New drug combo fights tough blood cancer
NCT ID NCT04214626
Summary
This study tested whether adding the drug lenalidomide to standard R-CHOP chemotherapy works better for people with medium-to-high risk diffuse large B-cell lymphoma. Researchers followed 60 previously untreated patients to see if this combination could keep the cancer from returning longer while being safe. They measured how many patients remained cancer-free after two years and tracked side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIFFUSE LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university
Zhengzhou, Henan, China
Conditions
Explore the condition pages connected to this study.